• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 1
  3. Author

Online ISSN: 2515-8260

Volume7, Issue1

Desmopressin Efficacy in Treatment of Nocturic Women- A Single-Blind Placebo-Controlled Study

    Mazin Adday Hasoon

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 1, Pages 50-57

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Nocturia is night waking for voiding, is a lower urinary tract problem of anxious symptom. nocturnal polyuria, diminished capacity of the bladder either nocturnal and/or global capacity, and sleep impairment are main pathophysiologic subtypes. fluid restriction mainly awhile before the bed time, anticholinergic therapy, diuretics and hormone replacement therapy are main preventive strategies. Aim of Study: To determine the oral desmopressin efficacy and safety of in nocturia of women as a treatment. Patients and methods: - Sixty-four women with18-80 years’ age with nocturia (nocturia index score >1, more than two voids per night) were invited to attend our study. randomly assigned patients into: 32 women received different desmopressin doses (0.2, 0.4, or 0.6 mg) during dose-titration period(three-weeks), and the other 32 ones received single- blind placebo treatment for 6 or 8 weeks according to their response. Results: In single-blind phase, for desmopressin, 30 (93.75 %) patients with fifty percent or more nocturnal voids reduction against the baseline levels in comparison to only 3 (9.7%)placebo-receiving patients where (P < 0.001). The mean nocturnal voids No., sleep period till 1st nocturnal void, nocturnal diuresis, and allover day volumes changed signscantly preferring desmopressin. (P
Keywords:
    Desmopressin efficacy nocturic women A single blind placebo
  • PDF (698 K)
  • XML
(2020). Desmopressin Efficacy in Treatment of Nocturic Women- A Single-Blind Placebo-Controlled Study. European Journal of Molecular & Clinical Medicine, 7(1), 50-57.
Mazin Adday Hasoon. "Desmopressin Efficacy in Treatment of Nocturic Women- A Single-Blind Placebo-Controlled Study". European Journal of Molecular & Clinical Medicine, 7, 1, 2020, 50-57.
(2020). 'Desmopressin Efficacy in Treatment of Nocturic Women- A Single-Blind Placebo-Controlled Study', European Journal of Molecular & Clinical Medicine, 7(1), pp. 50-57.
Desmopressin Efficacy in Treatment of Nocturic Women- A Single-Blind Placebo-Controlled Study. European Journal of Molecular & Clinical Medicine, 2020; 7(1): 50-57.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 211
  • PDF Download: 320
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus